A special 30th Anniversary research presentation on early recognition and progression of Alzheimer’s
disease and what the National Institute on Aging and the Alzheimer’s Association
are asking three of the country’s leading scientists to do about it.
Thursday, March 31, 2011, 7:00 p.m.
National Heritage Museum
33 Marrett Road
Lexington, MA 02421
(at the intersection of Route 2A and Mass. Ave)
Click here for directions
Moderated by Maria C. Carrillo, PhD
Senior Director, Medical & Scientific Relations
National Alzheimer’s Association
Free and open to the public. Seating is limited.
Registration and light refreshments at 6:00 pm
Guy M. McKhann, MD Chair, NIA/Alzheimer’s
Association Workgroup on Clinical Criteria
Professor of Neurology and Neuroscience, Johns Hopkins
University School of Medicine; Founding Director of The
Zanvyl Krieger Mind/Brain Institute, Johns Hopkins University
Marilyn Albert, PhD Chair, NIA/Alzheimer’s
Association Workgroup on Mild Cognitive Impairment
Director, Division of Cognitive Neuroscience, Johns Hopkins
University; Co-Director, John Hopkins Alzheimer’s Disease
Research Center; Professor of Neurology and Professor of
Psychiatry and Behavioral Sciences, Johns Hopkins
University School of Medicine
Reisa Sperling, MD Chair, NIA/Alzheimer’s
Association Workgroup on Pre-clinical Criteria
Director, Center for Alzheimer Research and Treatment,
Department of Neurology, Brigham and Women’s Hospital;
Co-Leader, Neuroimaging Program, Alzheimer’s Disease
Research Center, Massachusetts General Hospital;
Associate Professor of Neurology, Harvard Medical School
Register below |
Click to view a PDF of the invitation!

In response to the fast pace of our insight into Alzheimer’s
disease, the National Institute on Aging (NIA) and the
Alzheimer’s Association convened three workgroups to
explore the need for new diagnostic criteria that better
reflect the full continuum of the disease from its earliest
effects to its eventual impact on mental and physical
function.
Knowledge of how Alzheimer’s progresses over
time is often described as having three phases: a presymptomatic,
or preclinical, phase many years prior to
diagnosis; a symptomatic mid-course, usually referred
to as mild cognitive impairment (MCI), characterized
by mild problems in the ability to think, learn, and
remember, with some but not all people with MCI
progressing to dementia; and, at its most advanced,
Alzheimer’s dementia, reflected by a loss of the ability to
function independently and a substantial impairment in
cognitive function. |